SCHEMBL2761791

SCHEMBL2761791

COC(=O)c1c(O)c2ccc(OC3CCCCC3)cc2oc1=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 8/20 0.52
MAOA P21397 7/20 0.52
NQO1 P15559 2/20 0.44
KDM4E B2RXH2 6/20 0.44
ALDH1A1 P00352 5/20 0.44
HSD17B10 Q99714 4/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
HPGD P15428 5/20 0.44
POLB P06746 2/20 0.44
ESR1 P03372 1/20 0.44
NR4A1 P22736 1/20 0.44
APEX1 P27695 1/20 0.44
ESR2 Q92731 1/20 0.44
CTDSP1 Q9GZU7 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
LMNA P02545 2/20 0.42
TP53 P04637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2761689 0.83 MAOB (0.48) MAOBMAOANQO1KDM4EALDH1A1
SCHEMBL2761690 0.83 MAOB (0.48) MAOBMAOANQO1KDM4EALDH1A1
SCHEMBL2762089 0.82 MAOB (0.50) MAOBMAOAKDM4EALDH1A1MEN1
SCHEMBL27771378 0.77 MAOB (0.78) MAOBMAOAKDM4EALDH1A1HSD17B10
SCHEMBL2761902 0.76 MEN1 (0.44) MAOBMAOANQO1ALDH1A1HPGD
SCHEMBL2761629 0.75 LMNA (0.47) MAOBMAOANQO1KDM4EALDH1A1
SCHEMBL2761686 0.74 CA12 (0.57) MAOANQO1KDM4EALDH1A1HSD17B10
SCHEMBL2761625 0.74 ALDH1A1 (0.48) MAOBNQO1KDM4EALDH1A1SMN1; SMN2
SCHEMBL2761681 0.73 MAOB (0.62) MAOBMAOAKDM4EALDH1A1HSD17B10
SCHEMBL26766997 0.73 MAPT (0.55) MAOBMAOAKDM4EALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324405-B2 Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors FIBROGEN, INC. (US) 2012-12-04 US disclosed
US-20100331400-A1 CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS FIBROGEN, INC. 2010-12-30 US disclosed
WO-2009100250-A1 CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS FIBROGEN, INC. (US) 2009-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331400-A1 CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS HIF1AN, HIF1A, EGLN2 MAOB 424/4885MAOA 321/4885NQO1 69/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.